Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

19 Jun, 2017, 09:00 ET New Medical Cannabis Joint Venture: LeafCann and iCAN: Israel-Cannabis Form iCAN: Australia

iCAN: Israel-Cannabis (iCAN), a leading Israeli developer of medical cannabis formulations, clinical trials and cannabis testing, has formed a...


19 Jun, 2017, 09:00 ET goBalto and Informa Partner to Accelerate Site Selection for Global Clinical Trials

goBalto, Inc., the leading provider of cloud-based clinical study startup (SSU) solutions, announced today its partnership with Citeline, part of...


19 Jun, 2017, 09:00 ET ¿Está su médico prescribiendo el tratamiento equivocado para la conjuntivitis?

Un nuevo estudio sugiere que la mayoría de las personas con la conjuntivitis aguda están recibiendo el tratamiento equivocado. A casi el 60 por...


19 Jun, 2017, 08:05 ET Biostage Announces Positive Preclinical Data of Cellspan™ Esophageal Implant Presented at the International Society for Stem Cell Research 2017 Annual Meeting

Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and...


19 Jun, 2017, 08:00 ET Complementary Preclinical Studies Published in Neuro-Oncology Demonstrate Immune Activation Mechanism of Tocagen's Toca 511 & Toca FC

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the publication of preclinical data in...


19 Jun, 2017, 08:00 ET Analgesic Solutions Presents Data on the use of MADDERS® to Assess Potentially Abuse-Related Events in Clinical Trials at the 79th Annual Scientific Meeting of The College on Problems of Drug Dependence

Analgesic Solutions is participating in the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting in Montreal, June 17-22,...


19 Jun, 2017, 08:00 ET Aldeyra Therapeutics to Present Novel Data on the Anti-Inflammatory Mechanism and Activity of ADX-102 at the World Congress on Inflammation 2017 Annual Meeting

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of...


19 Jun, 2017, 07:30 ET Gamida Cell Announces $40 Million Private Financing

Financing provides strong base to complete Phase 3 clinical trial and commercialization of lead product candidate NiCord® for blood cancers...


19 Jun, 2017, 07:00 ET European Investment Bank (EIB) Supports Late-Stage Development and Production of BiondVax's Universal Flu Vaccine Candidate Under Horizon 2020 Initiative

The European Investment Bank (EIB) and BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate...


19 Jun, 2017, 06:55 ET Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that it has enrolled the last patient in the ongoing CARRIE study, a Phase 2,...


19 Jun, 2017, 06:01 ET Sciton Women's Health Group Announces Presentation of diVa® Hybrid Laser Pilot Study Clinical Data at International Urogynecological Association 42nd 2017 Annual Meeting

PALO ALTO, Calif., June 19, 2017 /PRNewswire/ - Sciton, Inc. Women's Health Group today announced interim and final results of a pilot study of...


19 Jun, 2017, 06:01 ET Tessa Therapeutics and Parker Institute for Cancer Immunotherapy Enter into Strategic Alliance Agreement

Tessa Therapeutics (Tessa) and the Parker Institute for Cancer Immunotherapy (Parker Institute) today announced the establishment of a multi-year...


19 Jun, 2017, 06:00 ET Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and...


19 Jun, 2017, 01:30 ET Erste Evidenzdaten aus der Versorgungsforschung zeigen den langfristigen Nutzen von sublingualer Immuntherapie bei der Behandlung von allergischer Rhinitis und Potential zur Prävention von allergischem Asthma

- Die allergische Rhinitis ist ein weit verbreiteter, chronischer und oft zu gesundheitlichen Einschränkungen führender Zustand, an dem weltweit...


19 Jun, 2017, 01:30 ET Une première étude fondée sur des données en vie réelle démontre les bénéfices à long terme de l'immunothérapie sublinguale dans le contrôle de la rhinite allergique et, potentiellement, la prévention de l'asthme allergique

- La rhinite allergique est une maladie fréquente, chronique et souvent invalidante qui touche approximativement 500 millions de personnes dans le...


16 Jun, 2017, 08:31 ET BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 Congress

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in a late breaking abstract session at the...


16 Jun, 2017, 08:30 ET DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma ("GBM") at SNO's Pediatric Neuro-Oncology Basic and Translational Research Conference

DelMar Pharmaceuticals (Nasdaq: DMPI) ("DelMar" and "The Company"), a biopharmaceutical company focused on the development of unique new cancer...


16 Jun, 2017, 08:00 ET Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...


16 Jun, 2017, 05:10 ET EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks

Eli Lilly and Company (NYSE: LLY) announced today that the majority of patients with active psoriatic arthritis (PsA) treated with Taltz®...


16 Jun, 2017, 04:15 ET New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced a new pooled analysis of data from eight Olumiant®...


15 Jun, 2017, 12:57 ET Scientific And Clinical Review Confirms Potential Of MiMedx dHACM Allografts For Regenerative Applications In Orthopedics

MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing...


15 Jun, 2017, 10:47 ET Erste komplette Struktur eines GPCR der Klasse B offenbart bislang unbekannte Mechanismen der Rezeptoraktivierung

- Struktur eines humanen Glucagonrezeptors entfacht neues Interesse für GPCR-Forschung Wissenschaftler vom Shanghai Institute of Materia...


15 Jun, 2017, 10:35 ET EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors

Taltz also demonstrated significant improvements in key secondary measures at 24 weeks Eli Lilly and Company (NYSE: LLY) announced today...